The Patent Finder
OP

Othair Prothena Limited

First filing 2021
OverviewNotableFeesChangesFamiliesPatent listSources & methods

10 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in May 2041. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2041
Next term end
3
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 3 fees due Oct 2 to 23, 2027 · next Oct 2

Which patents, and when each one lapses · Pro

Recent changes

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 10 of 10

PatentTitleStatusExpiresConfidence
US 11,945,849Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease
In force
 · Medium confidence
In forceMedium confidence
US 11,952,406Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease
In force
 · Medium confidence
In forceMedium confidence
US 11,965,005Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease
In force
 · Medium confidence
In forceMedium confidence
US 12,247,056Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease
In force
 · Medium confidence
In forceMedium confidence
US 11,434,283Anti-Abeta Antibodies
In force
 · High confidence
In forceHigh confidence
US 11,434,284Anti-Abeta Antibodies
In force
 · High confidence
In forceHigh confidence
US 11,434,285Anti-Abeta Antibodies
In force
 · High confidence
In forceHigh confidence
US 11,440,953Anti-Abeta Antibodies
In force
 · High confidence
In forceHigh confidence
US 12,435,129Anti-Abeta Antibodies
In force
 · High confidence
In forceHigh confidence
US 12,661,392Multiepitope Vaccine for the Treatment of Alzheimer's Disease
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 10: 10 applications pending · 2 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
4 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited